TK neoantigen vaccine

TK neoantigen vaccine is an investigational **personalized therapeutic cancer vaccine** being developed by Takis and Evvivax using a **linear DNA** vaccine approach. It is designed to encode multiple patient-specific tumor neoantigen epitopes identified from an individual patient's tumor, with the goal of inducing neoantigen-specific antitumor T-cell responses against cancer cells while sparing normal tissues. Publicly available information appears limited and largely preclinical or platform-level, but the program has been described as part of Takis and Evvivax's anti-cancer vaccine strategy for personalized oncology.

Other names

Takis TK neoantigen vaccine